Invention Grant
- Patent Title: Method of predicting a predisposition to QT prolongation
-
Application No.: US15705054Application Date: 2017-09-14
-
Publication No.: US10563260B2Publication Date: 2020-02-18
- Inventor: Christian Lavedan , Simona Volpi , Louis Licamele
- Applicant: Vanda Pharmaceuticals, Inc.
- Applicant Address: US DC Washington
- Assignee: VANDA PHARMACEUTICALS, INC.
- Current Assignee: VANDA PHARMACEUTICALS, INC.
- Current Assignee Address: US DC Washington
- Agency: Hoffman Warnick LLC
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12Q1/6883
Abstract:
The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Public/Granted literature
- US20180002757A1 METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION Public/Granted day:2018-01-04
Information query
